Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Costco

D.R. Horton

First Republic

Lennar

Pfizer

SVB Financial Group

Sanofi

Target

Toll Brothers

Walmart

SPDR S&P Homebuilders ETF

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

Pfizer CEO Albert Bourla said it will deliver Seagen's cancer therapy to the world at a scale that hasn't been seen before with its $43 billion acquisition.

Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal

Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive.

Pfizer Overpays for Seagen, but Who's Counting

Pfizer (NYSE: PFE) is buying Seagen Inc. (Nasdaq: SGEN) for $43 billion. These are the details.

Pfizer Buying Seagen For $43 Billion: Details (PFE) (SGEN)

MILWAUKEE , March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Seagen (Nasdaq: SGEN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.  Click here to learn how to join the action https://www.ademilaw.com/case/seagen-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Seagen Inc. has obtained a Fair Price in its transaction with Pfizer

The latest deal comes as Pfizer seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs and decline in demand for its COVID products.

Pfizer to pay $43B for Seagen, boosting cancer drug portfolio

Pfizer plans to acquire Seagen for around $43 billion. Investors appear to have already been betting the deal would happen after several weeks of rumors about a potential buyout.

Why Seagen Stock Is Soaring Today

Seagen Inc (NASDAQ:SGEN) stock is soaring today, after news that Pfizer (PFE) is acquiring the company for roughly $43 billion, expanding its access to cancer treatment.

Seagen Stock Boosted on Billion-Dollar Buyout

Pfizer is buying Seattle-area biotech giant Seagen in a massive $43 billion deal announced Monday.

Pfizer will acquire Seattle-area biotech giant Seagen for $43 billion

Seagen (NASDAQ: SGEN ) stock is taking off on Monday as investors react to an acquisition deal with Pfizer (NYSE: PFE ). Pfizer is acquiring Seagen for $43 billion in cash.

SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal

Pfizer Inc (NYSE:PFE) announced it would be acquiring cancer drugmaker Seagen Inc, adding four approved cancer therapies with combined sales of nearly $2 billion in 2022 to its portfolio. Pfizer said in a statement it will acquire Seagen for $229 per share in cash for a total enterprise value of approximately $43 billion.

Pfizer to acquire cancer drugmaker Seagen for $43B

Pfizer struck a deal for drugmaker Seagen, spending some of its COVID-19 vaccine cash to expand in oncology.

Pfizer just made a $43 billion bet on a precise new way of attacking cancer

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal

The New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.

Pfizer Agrees to Buy Seagen for $43 Billion

Pfizer will pay $229 a share in cash for Seagen.

Pfizer to Buy Seagen for $43 Billion

Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to pay $229 a share in cash for Seagen, which discovers and develops cancer drugs.

Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech's stock pops 20%

Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.

Pfizer looks beyond COVID sales with $43 bln deal for cancer drugmaker Seagen

NEW YORK & BOTHELL, Wash.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.

Pfizer Invests $43 Billion to Battle Cancer

– Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy – TOKYO and BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer

Axcelis Technologies

Arista Networks

Booking Hlds

Innovator IBD(R) Breakout Opportunities ETF

Cadence Design Systems

CECO Environmental Corp

Clean Harbors

Cirrus Logic

Genelux Corp

ON Semiconductor

Palo Alto Networks

Wingstop

As the market indexes fight for support, ANET, WING, BKNG, CDNS, PANW and more land a spot on the IBD Breakout Stocks Index. The post Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones appeared first on Investor's Business Daily.

Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones

Catalent

W.W. Grainger

Lucid Group

Liberty Media Corp-Liberty SiriusXM

Moderna

Match Group

Sirius XM Holdings Inc

West Pharmaceutical Services

Investing in large-cap stocks is considered one of the best ways to invest in the stock market.

The 5 Best and Worst Performing Large-Cap Stocks in February 2023

Amylyx Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Axsome Therapeutics

Cogint

CTI BioPharma

IVERIC bio Inc

Mirati Therapeutics

Reata Pharmaceuticals

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

The unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the attention of the world's largest drugmakers.

Seagen's Cancer Therapy Is Making It a Takeover Target

Albemarle

Krispy Kreme

Fisker Inc

Palantir Technologies

Tesla

Union Pacific

Vanguard S&P 500 ETF

Zillow

The stock market is digesting recent inflation data and earnings reports. Where is the stock market headed next?

U.S. Stock Market Today: Today's Biggest Market Movers

Rumors of another buyout are pushing the drugmaker's shares higher today.

Why Seagen Stock Perked Up Today

News for Seagen Stock (SGEN)